• PHP30 2006 DRUG PAYMENTS IN THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM- REIMBURSEMENT IMPLICATIONS

    Nov 1, 2004, 00:00

  • PDB2 EVALUATION OF IMPROVED UTILITY ESTIMATES IN COST EFFECTIVENESS ANALYSIS OF MULTIPLE COMPLICATIONS IN TYPE-2 DIABETES

    Nov 1, 2004, 00:00

  • POS6 COST-EFFECTIVENESS OF MIACALCIC IN TREATMENT OF PAIN DUE TO OSTEOPOROTIC VERTEBRAL FRACTURE

    Nov 1, 2004, 00:00

  • EEI SUNBURNS ACCORDING TO GENDER

    Nov 1, 2004, 00:00

  • PIN7 COST MINIMIZATION ANALYSIS OF ORAL VALGANCICLOVIR VS. INTRAVENOUS AND ORAL GANCICLOVIR IN THE PREVENTION OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS

    Nov 1, 2004, 00:00

  • PDB30 DRUG UTILIZATION OF GLITAZONES IN ITALY

    Nov 1, 2004, 00:00

  • PCV58 CHRONIC VENOUS DISEASE- CARE IMPACT

    Nov 1, 2004, 00:00

  • PAR 18 ASSESSMENT OF HEALTH STATUS IN A NATIONAL SAMPLE OF U.S. OSTEOARTHRITIC PATIENTS

    Nov 1, 2004, 00:00

  • PCVII COST EFFECTIVENESS OF ADDING NIASPANTO ATORVASTATIN TREATMENT IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH DYSLIPIDEMIA IN THE UK

    Nov 1, 2004, 00:00

  • PIN10 COST-EFFECTIVENESS OF EXPANDED HIV SCREENING OF BLOOD DONATIONS IN GHANA

    Nov 1, 2004, 00:00

  • PGI12 HEALTH-RELATED QUALITY OF LIFE AND PATIENT SELFPERCEIVED HEALTH STATUS IN IBS

    Nov 1, 2004, 00:00

  • PCN43 MAPPING HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASUREMENTS INTO GENERIC UTILITY MEASURES (EQ-5D)- A CASE STUDYWITH BORTEZOMIB (VELCADE)

    Nov 1, 2004, 00:00

  • PUK23 LANTHANUM CARBONATE FOR THE TREATMENT OF HYPERPHOSPHATAEMIA- DEVELOPMENT OF A COSTEFFECTIVENESS MODEL

    Nov 1, 2004, 00:00

  • IN4 POPULATION-BASED EVALUATION OF FUTURE BURDEN OF DISEASE AND COSTS RELATED TO CHRONIC HEPATITIS C AND ANTIVIRAL TREATMENT STRATEGIES

    Nov 1, 2004, 00:00

  • PCV27 COST-EFFECTIVENESS OF BUPROPION IN SMOKING CESSATION IN FINLAND

    Nov 1, 2004, 00:00

  • PCV56 PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERCHOLESTEROLEMIA AMONG CHINESE AMERICANS

    Nov 1, 2004, 00:00

  • PES21 HAIR LOSS, QUALITY OF LIFE IMPACT

    Nov 1, 2004, 00:00

  • PCN20 COSTS OF TREATING ADVANCED NON-SMALL-CELL LUNG CANCER IN SPAIN USING GEMCITABINE IN COMBINATION WITH CISPLATIN- A COMPARISON WITH OTHER 2ND GENERATION NOVEL AGENTS

    Nov 1, 2004, 00:00

  • PPN9 AGREEMENT BETWEEN PATIENTS- REPORTED OUTCOMES IN 3 CHRONIC DISEASES

    Nov 1, 2004, 00:00

  • PPN12 DEVELOPMENT OF TWO INSTRUMENTS TO CAPTURE EASE-OF-CARE OUTCOMES IN HEALTH-CARE PROVIDERS WHO CARE FOR PATIENTS TREATED WITH PCA DELIVERY SYSTEMS

    Nov 1, 2004, 00:00

  • PCV8 THE ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)- POLISH PERSPECTIVE

    Nov 1, 2004, 00:00

  • PHP1 RETAIL PRICES DECREASED 30 IN FINLAND IN 1994-2003 EVEN BEFORE INTRODUCTION OF GENERIC SUBSTITUTIONS COHORT ANALYSIS

    Nov 1, 2004, 00:00

  • PHP27 AGE AND GENDER DISTRIBUTION OF PHARMACEUTICAL EXPENDITURE PER INHABITANT

    Nov 1, 2004, 00:00

  • PGI1 ECONOMIC EVALUATION OF ON-DEMAND MAINTENANCE THERAPY WITH PROTON PUMP INHIBITORS IN PATIENTS WITH SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE-A MONTE-CARLO ANALYSIS FOR ITALY

    Nov 1, 2004, 00:00

  • PHPI8 INTRODUCING THE FOURTH HURDLE' IN THE NEW EUROPEAN UNION MEMBER STATES- THE CASE OF HUNGARY

    Nov 1, 2004, 00:00

  • PIN30 FREQUENCY OF POTENTIAL DRUG-DRUG INTERACTIONS WITH TRIAZOLE ANTIFUNGAL USE IN DUTCH HOSPITAL SETTINGS

    Nov 1, 2004, 00:00

  • PIN3 LINEZOLID FOR THE TREATMENT OF SKIN AND SOFT-TISSUE MRSA INFECTIONS-A COST-EFFECTIVE ALTERNATIVE TO VANCOMYCIN- EVIDENCE FROM A MULTINATIONAL CLINICAL TRIAL

    Nov 1, 2004, 00:00

  • PIN11 PHARMACOECONOMIC EVALUATION OF HERD PROTECTION FOR THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN SWITZERLAND

    Nov 1, 2004, 00:00

  • PMH15 ANNUAL SOCIETAL COSTS AND QUALITY OF LIFE IN CHILDREN WITH NEUROPSYCHIATRIC DISORDERS IN SWEDEN

    Nov 1, 2004, 00:00

  • MH2 MODELING ANTIPSYCHOTICS MARKET SHARE EVOLUTION TREATMENT

    Nov 1, 2004, 00:00

  • PIN8 ECONOMIC EVALUATION OF HIV TREATMENTS- THE I.CO.N.A. COHORT STUDY

    Nov 1, 2004, 00:00

  • PUK7 WHEN SHOULD ERYTHROPOIETIN (EPO) BE REPLACED BY PACKED RED BLOOD CELL TRANSFUSION (TR) IN HEMODIALYSIS (HD) PATIENTS?

    Nov 1, 2004, 00:00

  • PRS6 A CANADIAN COST ANALYSIS OF 4 RANDOMIZED DOUBLEBLIND ACTIVE COMPARATOR TRIALS WITH TELITHROMYCIN IN ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB) AND COMMUNITY-ACQUIRED PNEUMONIA (CAP)

    Nov 1, 2004, 00:00

  • PMC10 ASP PLUS SIX PERCENT IN 2005-A CONCEPTUAL VIEW OF FUTURE PHYSICIAN PAYMENTS FOR DRUGS AND THEIR ADMINISTRATION IN THE OFFICE SETTING

    Nov 1, 2004, 00:00

  • CV4 EVALUATION OF SURVIVAL AND ISCHAEMIC AND THROMBOEMBOLIC EVENT RATES IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN THE GENERAL POPULATION WHEN TREATED AND UNTREATED WITH WARFARIN

    Nov 1, 2004, 00:00

  • PHP21 QUALITY ASSESSMENT OF AN AMBULATORY CARE CLINIC BASED COLLABORATIVE CARE APPROACH FOR ACHIEVING THERAPEUTIC GOALS

    Nov 1, 2004, 00:00

  • PNL22 EFFECT OF DISEASE-SPECIFIC COMPLICATIONS ON THE PREDICTION OF UTILITIES IN PARKINSONS DISEASE

    Nov 1, 2004, 00:00

  • PMC12 EVALUATING DRUG SAFETY USING STOCHASTIC SIMULATION MODELS

    Nov 1, 2004, 00:00

  • PNL19 VALIDATING THE RESTLESS LEGS SYNDROME QUALITY OF LIFE QUESTIONNAIRE (RLSQOL) IN A TRIAL PATIENT POPULATION

    Nov 1, 2004, 00:00

  • PUK22 DERIVING UNIT COSTS FOR RESOURCE UTILISATION IN PROSPECTIVE URINARY INCONTINENCE RESEARCH (PURE)-AN OBSERVATIONAL STUDY IN 14 EUROPEAN COUNTRIES

    Nov 1, 2004, 00:00

  • PES10 A NATION-WIDE ESTIMATE OF NON-MEDICAL SOCIO-ECONOMIC CONSEQUENCES ATTRIBUTABLE TO VISUAL IMPAIRMENT IN FRANCE- A SOCIETAL PERSPECTIVE

    Nov 1, 2004, 00:00

  • CV7 MODELLING SURVIVAL AND COSTS IN SWITZERLAND OF NESIRITIDE VERSUS INOTROPIC THERAPY FOR ACUTE DECOMPENSATED HEART FAILURE

    Nov 1, 2004, 00:00

  • PPN11 DEVELOPMENT OF AN INSTRUMENT TO CAPTURE EASE-OFCARE OUTCOMES IN PATIENTS TREATED WITH PCA DELIVERY SYSTEMS

    Nov 1, 2004, 00:00

  • PBR4 COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN JAPAN

    Nov 1, 2004, 00:00

  • PAA2 PUBLIC HEATH SYSTEM EXPENSES ON CHILDRENS ATOPIC DERMATITIS TREATMENT IN VLADIVOSTOK CITY

    Nov 1, 2004, 00:00

  • PMC11 COMPARING DIFFERENT APPROXIMATION METHODS FOR REMAINING LIFE EXPECTANCY IN DECISION TREES

    Nov 1, 2004, 00:00

  • PMH20 PATIENT-REPORTED OUTCOMES- DO THEY AGREE WITH OBJECTIVE CAREGIVER-REPORTED OUTCOMES FOR INDIVIDUALS WITH SCHIZOPHRENIA RESIDING IN THE COMMUNITY?

    Nov 1, 2004, 00:00

  • PUK24 PREVALENCE AND QUALITY OF LIFE IN FRENCH WOMEN WITH STRESS URINARY INCONTINENCE

    Nov 1, 2004, 00:00

  • MC2 CORRECTING FOR COMPENSATING MECHANISMS RELATED TO PRODUCTIVITY COSTS IN ECONOMIC EVALUATIONS OF HEALTH CARE PROGRAMS

    Nov 1, 2004, 00:00

  • PCV33 MODELING THE ECONOMIC IMPACT OF NEW IMPLANTABLE DEFIBRILLATORS WITH A LONGER LIFETIME

    Nov 1, 2004, 00:00

  • PAAI LEVOCETIRIZINE REDUCES THE COST OF PER AND ITS CO-MORBIDITIES FOR SOCIETY AND EMPLOYERS

    Nov 1, 2004, 00:00

  • PHP19 EFFECTS OF DEVOLUTION OF SUBSIDIES FOR PHARMACEUTICALS IN SWEDEN

    Nov 1, 2004, 00:00

  • PCV71 EFFECT OF STATIN TITRATING ON CHOLESTEROL REDUCTION AND GOAL ATTAINMENT IN ACTUAL CLINICAL PRACTICE IN GERMANY

    Nov 1, 2004, 00:00

  • PDB1 ASSOCIATION OF PATIENTS KNOWLEDGE AND ADHERENCE TO MEDICAL ADVICE TO GLYCAEMIC CONTROL IN THE MANAGEMENT OF DIABETES MELLITUS

    Nov 1, 2004, 00:00

  • PHP23 ANALYSIS OF CLINICAL INTERVENTION DOCUMENTATION BY PHARMACISTS

    Nov 1, 2004, 00:00

  • PIN20 COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND CASPOFUNGIN FOR THE TREATMENT OF INVASIVE CANDIDA AND ASPERGILLOSIS INFECTIONS IN SPAIN

    Nov 1, 2004, 00:00

  • PCV52 VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) QUESTIONNAIRE

    Nov 1, 2004, 00:00

  • PGI11 PSYCHOMETRIC VALIDATION OF TWO GASTROINTESTINAL (GI)-SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN RENAL TRANSPLANT PATIENTS WITH AND WITHOUT GI COMPLICATIONS

    Nov 1, 2004, 00:00

  • QL3 QUALITY OF LIFE OF GASTROESOPHAGEL REFLUX DISEASE PATIENTS

    Nov 1, 2004, 00:00

  • PAR22 FIBROMYALGIA SYNDROM- A FRENCH EPIDEMIOLOGICAL SURVEY

    Nov 1, 2004, 00:00

  • PUK1 THE COST-EFFECTIVENESS OF EXTENDED RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN GERMANY AND THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PHP3 APPLICATION OF THE DELPHI TECHNIQUE IN THE DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR USE IN METHADONE MAINTENANCE PROGRAMS

    Nov 1, 2004, 00:00

  • PMW4 VALIDATION OF THE SPANISH VERSION OF THE SELFESTEEM AND RELATIONSHIP (SEAR) QUESTIONNAIRE FOR MEN WITH ERECTILE DYSFUNCTION (ED)

    Nov 1, 2004, 00:00

  • CV2 CHOLESTEROL ATTAINMENT IN DYSLIPIDAEMIC TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE

    Nov 1, 2004, 00:00

  • PHP15 PREFERENCES MATTER- UNDERSTANDING DEMAND FOR VOLUNTARY HEALTH INSURANCE

    Nov 1, 2004, 00:00

  • PUK19 DEVELOPMENT OF A QUESTIONNAIRE TO ASSESS QUALITY OF CARE IN DUTCH DIALYSIS CENTRES

    Nov 1, 2004, 00:00

  • PMH14 THE HEATLH-RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE COSTS TO SOCIETY

    Nov 1, 2004, 00:00

  • PDB7 LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS INSULIN GLARGINE IN INSULIN NAVE PATIENTS WITH TYPE-2 DIABETES POORLY CONTROLLED ON ORAL HYPOGLYCEMIC AGENTS IN DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPA ...

    Nov 1, 2004, 00:00

  • PGI4 USE OF CAPSULE ENDOSCOPY IN DIAGNOSING OBSCURE GASTROINTESTINAL BLEEDING- COST-EFFECTIVENESS EVALUATION FROM A EUROPEAN PERSPECTIVE

    Nov 1, 2004, 00:00

  • PES4 EFFECT OF CIRCADIAN INTRA-OCULAR PRESSURE VARIATIONS ON THERAPEUTIC DECISION MAKING- A MODELING APPROACH BASED ON A RANDOMIZED CLINICAL TRIAL

    Nov 1, 2004, 00:00

  • PCN23 A COST MINIMIZATION ANALYSIS OF FIRST-LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2004, 00:00

  • PAR4 THE COART STUDY- THE COST OF OSTEOARTHRITIS IN FRANCE BETWEEN 1991 AND 2002

    Nov 1, 2004, 00:00

  • PCV45 A SHORT-TERM RETROSPECTIVE ECONOMIC EVALUATION FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION WITH ANGIOTENSIN ll-ANTAGONISTS IN SPAIN

    Nov 1, 2004, 00:00

  • PMH11 PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM VERSUS CITALOPRAM IN THE TREATMENT OF SEVERE DEPRESSION IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PDB3 COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR COMPARED TO NPH INSULIN IN PATIENTS WITH TYPE-2 DIABETES IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PMH17 COST-UTILITY ANALYSIS OF MEDICAL CO-PRESCRIPTION OF HEROIN COMPARED WITH METHADONE MAINTENANCE TREATMENT FOR CHRONIC, TREATMENT RESISTANT HEROIN ADDICTS

    Nov 1, 2004, 00:00

  • PCVI8 COSTS OF HYPERTENSION IN THE ELDERLY IN COMPARISON WITH PATIENTS UNDER 65 IN POLAND

    Nov 1, 2004, 00:00

  • POS4 COST-EFFECTIVENESS OF BONE STIMULATORS IN THE CONSERVATIVE TREATMENT OF STABLE NONUNION FRACTURES

    Nov 1, 2004, 00:00

  • PCV9 COST-EFFECTIVENESS ANALYSIS OF ALTEPLASE COMPARED WITH STREPTOKINASE AND ABSENCE OF THROMBOLYTICAL THERAPY FOR MYOCARDIAL INFARCTION

    Nov 1, 2004, 00:00

  • PIN4 COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF VENTILATORASSOCIATED PNEUMONIA IN SPAIN

    Nov 1, 2004, 00:00

  • PHP22 MEDICATION AND SOCIO-ECONOMIC STATUS IN A POPULATION-BASED COHORT STUDY

    Nov 1, 2004, 00:00

  • PCN5 COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC)- A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

    Nov 1, 2004, 00:00

  • PDB24 CONTINGENT VALUATION OF AN INHALED DELIVERY SYSTEM FOR INSULIN

    Nov 1, 2004, 00:00

  • PIN16 ECONOMIC BURDEN AND FACTORS INFLUENCING COSTS IN GERMAN PATIENTS HOSPITALISED FOR COMMUNITYACQUIRED PNEUMONIA (CAP)

    Nov 1, 2004, 00:00

  • CN1 TRENDS IN OUTCOMES AND COSTS FOR U.S. PATIENTS WITH ADVANCED NON-SMALL LUNG CANCER 1994-2001

    Nov 1, 2004, 00:00

  • PCV55 DISEASE SPECIFIC VERSUS GENERIC OUTCOME ASSESSMENT IN PULMONARY HYPERTENSION

    Nov 1, 2004, 00:00

  • MH1 INCREMENTAL COST-EFFECTIVENESS OF THREE CLASSES OF ANTI-DEPRESSANTS- RESULTS FROM A UK RANDOMISED TRIAL

    Nov 1, 2004, 00:00

  • PNL11 EFFECT OF COMORBIDITIES ON MEDICAL CARE USE AND COST AMONG PATIENTS WITH PARTIAL SEIZURE DISORDER

    Nov 1, 2004, 00:00

  • PARI HE BURDEN OFANKYLOSING SPONDYLITIS IN AUSTRALIA AN EPIDEMIOLOGICALAND COST OF ILLNESS MODEL

    Nov 1, 2004, 00:00

  • PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

    Nov 1, 2004, 00:00

  • DB1 ASSOCIATION BETWEEN ANTIPSYCHOTIC DRUGS AND DIABETES MELLITUS- A PHARMO STUDY

    Nov 1, 2004, 00:00

  • PIN25 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE MEASURES IN HIV AND AIDS

    Nov 1, 2004, 00:00

  • PNL31 NEUROPATHIC PAIN (NEP) IMPACT ON PATIENT MENTAL FUNCTIONING, SYMPTOM LEVELS OF ANXIETY AND DEPRESSION, AND SLEEP DISTURBANCE- RESULTS FROM THE DONEGA STUDY

    Nov 1, 2004, 00:00

  • PIN27 WILLINGNESS TO PAY FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (TB) IN RURAL NEPAL- A CONTINGENT VALUATION STUDY

    Nov 1, 2004, 00:00

  • PCV20 COST EFFECTIVENESS OF ANTIHYPERTENSIVE MONO-THERAPYWITH PERINDOPRIL OR ENALAPRIL IN ELDERLY PATIENTS FROM THE THIRD PARTY PAYER PERSPECTIVE

    Nov 1, 2004, 00:00

  • PHP11 PRESCRIBING PATTERNS OF CIPROFLOXACIN AND LEVOFLOXACIN IN AN ITALIAN GERIATRIC HOSPITAL

    Nov 1, 2004, 00:00

  • PCN7 THE LIFETIME COST OF GEFITINIB ('IRESSA') IN TREATING PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)

    Nov 1, 2004, 00:00

  • PCV36 ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH STATINS IN ITALY

    Nov 1, 2004, 00:00

  • PCV25 SMOKING CESSATION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE-A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2004, 00:00

  • PCV22 THE COST EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY (HRT) FOR WOMEN WITH MENOPASUAL SYMPTOMS IN SWEDEN

    Nov 1, 2004, 00:00

  • PAR25 CROSS-VALIDATION OF A NEW QUESTIONNAIRE DESIGNED TO PREDICT FUTURE RISK OF NSAID-INDUCED GASTROINTESTINAL EVENTS

    Nov 1, 2004, 00:00

  • QL2 THE HEALTH RELATED QUALITY OF LIFE IN PARKINSONS DISEASE IN GERMANY

    Nov 1, 2004, 00:00

  • PCV48 ARIAL FIBRILLATION HISTORY AND ATRIOVENTRICULAR BLOCK APPEARANCE IN PATIENTS WITH SINUS NODE DISEASE AND SINGLE CHAMBER ATRIAL PACEMAKER-IMPACT ON COST OF THERAPY

    Nov 1, 2004, 00:00

  • PCV59 CHRONIC VENOUS DISEASE-THROUGH BODY MASS INDEX

    Nov 1, 2004, 00:00

  • PDB19 COST OF HOSPITAL ADMISSIONS FOR CARDIOVASCULAR DISEASE OVER FIVE YEARS IN PATIENTS WITH DIABETES MELLITUS

    Nov 1, 2004, 00:00

  • PCN34 UTILITY ASSOCIATED WITH SEVERITY OF CANCER-RELATED ANAEMIA (CRA)- A SOCIETAL VALUATION

    Nov 1, 2004, 00:00

  • PAR5 MESSAGE- AN OBSERVATIONAL POST-LAUNCH STUDYTO ASSESS EFFECTIVENESS AND COST OF SUPLASYN IN PATIENTS WITH KNEE OSTEOARTHRITIS

    Nov 1, 2004, 00:00

  • PCN4I ASSESSMENT OF DIFFERENT STRATEGIES FOR DETERMINING DIAGNOSIS AND RESECTABILITY IN PATIENTS WITH SUSPECTED PANCREATIC CANCER

    Nov 1, 2004, 00:00

  • PUK14 ELDERLY PATIENTS STARTING RENAL REPLACEMENT THERAPY (RRT) HAVE LOWER LOSS OF HEALTH RELATED QUALITY OF LIFE (HRQL) THAN YOUNGER ONES DURING THE FIRST TWO YEARS

    Nov 1, 2004, 00:00

  • PHP12 COST VARIANCES IN G-DRG GROUPS. THE EXAMPLE OF RHBMP-2 IN SPINE FUSION SURGERY

    Nov 1, 2004, 00:00

  • HP7 STRATEGIES OF PRIORIZATION BASED ON THE SOCIAL WELFARE FUNCTION

    Nov 1, 2004, 00:00

  • PHP26 PHYSICIANSACTIVITY HETEROGENEITY- AN EMPIRICAL STUDY IN TWO FRENCH REGIONS

    Nov 1, 2004, 00:00

  • PBR6 ISAM- INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT.THE ITALIAN EXPERIENCE

    Nov 1, 2004, 00:00

  • PMH28 METABOLIC OUTCOMES OF ANTIPSYCHOTICS IN SCHIZOPHRENIA- A MARKOV MODEL

    Nov 1, 2004, 00:00

  • PCVI5 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH IN SPAIN- AN ECONOMIC EVALUATION BASED ON THE LIFE TRIAL

    Nov 1, 2004, 00:00

  • PNL26 A NEW SCREENING TOOL FOR MIGRAINE IN THE GENERAL POPULATION- THE MIGRAINE-SCREEN-Q (MS-Q)

    Nov 1, 2004, 00:00

  • PCNI9 NEW TARGETED THERAPY FOR PATIENTS WITH PREVIOUSLY-TREATED ADVANCED NON-SMALL CELL LUNG CANCER-GEFITINIB ('IRESSA')

    Nov 1, 2004, 00:00

  • UC4 VARIATION IN ADL FUNCTIONING WITHIN BARTHEL INDEX SCORES-IMPLICATIONS FOR STROKE CLINICAL TRIALS AND PRACTICE

    Nov 1, 2004, 00:00

  • PCV38 COSTS OF MYOCARDIAL INFARCTION TREATMENT IN RUSSIAN FEDERATION

    Nov 1, 2004, 00:00

  • PIN23 PROSPECTIVE STUDY ON ACUTE LOWER RESPIRATORY TRACT INFECTION IN CHILDREN YOUNGER THAN 3 YEARS IN GERMANY (PRI.DE)-ECONOMIC IMPACT OF COMMUNITY-ACQUIRED CASES TREATED BY OFFICE-BASED PEDIATRICIANS (PRIMARY CARE)

    Nov 1, 2004, 00:00

  • PCN40 DISPARITIES IN MEDICAID CANCER EXPENDITURES

    Nov 1, 2004, 00:00

  • PHP4 PERSPECTIVE OF THE GENERIC MARKET IN FRANCE- 2004-2008

    Nov 1, 2004, 00:00

  • PGI2 THE ECONOMIC EVALUATION OF A RANDOMIZED TRIAL COMPARING 'TEST-AND-TREAT' WITH PROMPT ENDOSCOPY IN PRIMARY CARE; THE HEALTH ECONOMICS OF THE SENSE-STUDY

    Nov 1, 2004, 00:00

  • PCV5 LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION IN GERMANY

    Nov 1, 2004, 00:00

  • PCV57 CHRONIC VENOUS DISEASE- COMPLIANCE WITH TREATMENT

    Nov 1, 2004, 00:00

  • PCN3I EVALUATION OF PEMETREXED VERSUS DOCETAXEL IN THE SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER- PATIENT PREFERENCE AND WILLINGNESS-TO-PAYWITH DISCRETE CHOICE CONJOINT ANALYSIS

    Nov 1, 2004, 00:00

  • PMW3 IMPROVING THE DELIVERY OF CHILD AND MATERNAL HEALTH CARE IN A POOR SETTING- COSTS AND BARRIERS TO BE CONSIDERED IN THE IMPLEMENTATION OF WHO MOTHER-BABY PACKAGE IN MORELOS, MEXICO

    Nov 1, 2004, 00:00

  • PHP24 ANALYSIS OF 'INNOVATOR' DRUGS FINANCED BY SPANISH NATIONAL HEALTH SERVICE OVER THE PERIOD 1996-2003

    Nov 1, 2004, 00:00

  • PMC9 HEALTH PROGRAM IMPACT EVALUATION USING OBSERVED AND EXPECTED TIME SERIES OF PHARMACEUTICAL CONSUMPTIONS

    Nov 1, 2004, 00:00

  • PCN38 THE IMPACT OF SCREENING ADHERENCE ON MEDICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN GERMANY-A DECISION ANALYSIS

    Nov 1, 2004, 00:00

  • EE2 LIVING WITH A DERMATOSIS- A NATIONAL SURVEY OF DEPRESSIVE SYMPTOMATOLOGY IN BELGIUM

    Nov 1, 2004, 00:00

  • PCVI7 COSTS OF HYPERTENSION IN POLAND MEASURED FROM THE THIRD PARTY PAYER PERSPECTIVE IN COMPARISON WITH THE SOCIETAL PERSPECTIVE

    Nov 1, 2004, 00:00

  • PMH19 THE PERCEIVED BENEFITS OF DOSING SCHEDULES FOR CHILDREN WITH ADHD

    Nov 1, 2004, 00:00

  • PDB28 VALIDATION OF ORAL ANTIDIABETIC DRUGS PRESCRIPTIONS- THE VIEWS OF PRIMARY CARE PHYSICIANS

    Nov 1, 2004, 00:00

  • PCV37 ECONOMIC EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH INSURANCE (SHI) IN GERMANY

    Nov 1, 2004, 00:00

  • EE3 COST-EFFECTIVENESS OF TREATMENT FOR MODERATE-TO-SEVERE PSORIASIS

    Nov 1, 2004, 00:00

  • PGI13 EFFECT OF TEGASEROD IN WOMEN WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN SOUTH AFRICA

    Nov 1, 2004, 00:00

  • PMH22 INCIDENCE, PREVALENCE AND TREATMENT PATTERNS OF PATIENTS WITH ADHD SYMPTOMS IN THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PC03 DEVELOPMENT OF A COPD SEVERITY SCORE IN CLAIMS DATABASE

    Nov 1, 2004, 00:00

  • PCN32 INSTRUMENTS TO MEASURE PATIENT-REPORTED OUTCOMES AND PERCEPTIONS OF CANCER-RELATED FATIGUE- A REVIEW OF THE LITERATURE

    Nov 1, 2004, 00:00

  • PNL9 INDIRECT COSTS ASSOCIATED TO INSOMNIA IN OCCUPATIONAL HEALTH- THE SISYPHE STUDY

    Nov 1, 2004, 00:00

  • PCV72 CHOLESTEROL GOAL ATTAINMENT AMONG PATIENTS TREATED WITH LIPID LOWERING DRUGS IN HUNGARY

    Nov 1, 2004, 00:00

  • PIN24 IMPROVEMENT IN PATIENT-REPORTED DEPRESSION IN HIV PATIENTS EXPERIENCING GRADE 2 SIDE EFFECTS AFTER SUBSTITUTION OF THEIR PROTEASE INHIBITOR (PI)/NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) WITH LOPINAVIR/RITONAVIR (LPV/R)

    Nov 1, 2004, 00:00

  • PCN9 ATIME-IN-MOTION STUDY OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BREAST CANCER PATIENTS IN THE UK

    Nov 1, 2004, 00:00

  • PMH1 IMPACT OF WEIGHT GAIN ON TREATMENT EFFECTIVENESS WITH OLANZAPINE OR ARIPIPRAZOLE, CONSIDERING NONADHERENCE, RELAPSE AND COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA IN FINLAND

    Nov 1, 2004, 00:00

  • MC7 USING STATED RISK-BENEFIT TRADEOFF PREFERENCES TO IDENTIFY POTENTIAL THERAPEUTIC RISK-MANAGEMENT PROBLEMS

    Nov 1, 2004, 00:00

  • PCV28 COST-EFFECTIVENESS OF RAMIPRIL IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS- A SWISS PERSPECTIVE

    Nov 1, 2004, 00:00

  • QL1 AGREEMENT BETWEEN PATIENTS- REPORTED OUTCOMES IN LIPODYSTROPHY (HIV/AIDS)

    Nov 1, 2004, 00:00

  • PUK3 ECONOMIC ASSESSMENT OF URO-VAXOM IN FEMALE PATIENTS WITH RECURRENT URINARY TRACT INFECTION IN GERMANY

    Nov 1, 2004, 00:00

  • PBR5 COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS WITH FONDAPARINUX IN MAJOR ORTHOPAEDIC SURGERY IN SWITZERLAND

    Nov 1, 2004, 00:00

  • PCV4 FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION

    Nov 1, 2004, 00:00

  • PMW2 HOW MUCH DOES UNINTENDED PREGNANCY COST THE UK HEALTH CARE SYSTEM?

    Nov 1, 2004, 00:00

  • PRS7 THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE HAS A NEGATIVE IMPACT ON THE QUALITY OF LIFE OF THE PATIENT- THE RESULTS OF THE EPIDEPOC STUDY

    Nov 1, 2004, 00:00

  • HPI THE RELATIONSHIP BETWEEN HEALTH INSURANCE TYPE AND COSTS OF PRESCRIBED DRUGS

    Nov 1, 2004, 00:00

  • PCNI5 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT2)- A PATIENT-LEVEL COST COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN FRANCE

    Nov 1, 2004, 00:00

  • PCVI9 COST-EFFECTIVENESS ANALYSIS OF THE MANAGEMENT OF ARTERIAL HYPERTENSION

    Nov 1, 2004, 00:00

  • PDB32 LONG-TERM DIABETES COMPLICATIONS- INFLUENCE OF DELAY IN STARTING INTENSIFIED THERAPY AND OF PATIENT RATES TREATED TO TARGET A1C.ANALYSES WITH THE DIABETES MELLITUS MODEL (DMM)

    Nov 1, 2004, 00:00

  • PGI14 COST-EFFECTIVENESS EVALUATION FOR A NEW DIAGNOSTIC TEST CONSIDERING ALSO COSTS FOR FALSE NEGATIVE AND FALSE POSITIVE DIAGNOSES AT VARIOUS PREVALENCE RATES

    Nov 1, 2004, 00:00

  • PCNI3 COST-EFFECTIVENESS ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH CISPLATIN-ETOPOSIDE, CISPLATIN-WINORELBINE AND CISPLATIN-GEMCYTABINE

    Nov 1, 2004, 00:00

  • PIN17 THE COSTS OF SEVERE SEPSIS MANAGEMENT IN INTENSIVE CARE UNITS IN POLAND

    Nov 1, 2004, 00:00

  • PMH18 ASSESSING THE TOTAL COST OF CARE FOR CEREBRAL PALSY PATIENTS WHO USE BOTULINUM TOXIN TYPE A- AN APPROACH TO CONTROLLING BIAS IN CASE CONTROL STUDIES

    Nov 1, 2004, 00:00

  • PCV24 PHARMACOECONOMIC EVALUATION OF THE CIBIS-II TRIAL

    Nov 1, 2004, 00:00

  • PHP25 WILLINGNESS TO PAY VERSUS OUT OF POCKET PAYMENTS FOR HEALTH SERVICES UTILIZATION IN GREECE

    Nov 1, 2004, 00:00

  • PCV74 A METHOD FOR IDENTIFYING PATIENTS WITH CHRONIC ANGINA FROM ADMINISTRATIVE CLAIMS DATA

    Nov 1, 2004, 00:00

  • PHP2 IMPACT OF PRESCRIBING GUIDELINES FOR INPATIENT ANTICOAGULATION

    Nov 1, 2004, 00:00

  • PCV7 THE COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN POLAND

    Nov 1, 2004, 00:00

  • MC8 COMPARING THE INTERVAL PROPERTIES OF HEALTH-STATE VALUATIONS MEASURED USING THE VISUAL ANALOGUE SCALE AND RANK-BASED SCALING

    Nov 1, 2004, 00:00

  • PMH8 COSTS AND EFFECTS OF RISPERDAL CONSTA (TM) IN COMPARISON TO CONVENTIONAL DEPOT AND SHORTACTING ATYPICAL FORMULATIONS IN PORTUGAL

    Nov 1, 2004, 00:00

  • PGI8 PHARMACOECONOMIC ASPECTS OF CROHNS DISEASE IN SLOVAKIA

    Nov 1, 2004, 00:00

  • PIN22 MODELLING THE COST-EFFECTIVENESS OF ACTIVATED PROTEIN C (XIGRIS) TREATMENT OF SEPTIC PATIENTS ININTENSIVE CARE UNITS IN HUNGARY

    Nov 1, 2004, 00:00

  • PNL21 INDEPENDENT EFFECT OF DYSKINESIA ON HEALTHRELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSONS DISEASE-A MULTIVARIATE ANALYSIS

    Nov 1, 2004, 00:00

  • MC3 QALYS LACK QUALITY IN PAEDIATRIC CARE-A CRITICAL REVIEW OF PUBLISHED COST-UTILITY STUDIES IN CHILD HEALTH

    Nov 1, 2004, 00:00

  • PDB33 EAGLE-DIABETES MODEL- BASIC FEATURES AND INTERNAL VALIDATION OF SIMULATING LONG-TERM DIABETIC OUTCOMES AND RELATED COSTS

    Nov 1, 2004, 00:00

  • PPN5 PROSPECTIVE ASSESSMENT OF THE HEALTH AND ECONOMIC BURDEN OF NEUROPATHIC PAIN

    Nov 1, 2004, 00:00

  • CV8 PHARMACOECONOMIC CONSEQUENCES OF PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE CZECH REPUBLIC

    Nov 1, 2004, 00:00

  • PCV5I CHRONIC VENOUS DISEASE AND HEALTH STATUS

    Nov 1, 2004, 00:00

  • PAR 10 PATTERNS OF DOSING WITH ADALIMUMAB AMONG COMMERCIALLY INSURED PATIENTS

    Nov 1, 2004, 00:00

  • PMH25 EMERGENCY DEPARTMENTS-THE FRONT LINE OF SCHIZOPHRENIA MANAGEMENT?

    Nov 1, 2004, 00:00

  • PES7 A PHARMACOECONOMIC ANALYSIS OF THE FIXED COMBINATION LATANOPROST/TIMOLOL VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF PATIENTS WITH GLAUCOMA IN SPAIN

    Nov 1, 2004, 00:00

  • PCN25 COST-EFFECTIVENESS-ANALYSIS OF THE THERAPY OF STAGETI-T2 PROSTATE CANCER WITH PERMANENT SEED IMPLANTATION IN COMPARISON WITH RADICAL PROSTATECTOMY

    Nov 1, 2004, 00:00

  • PHP33 SATISFACTION AMONG GERMAN PHYSICIANS-A REPRESENTATIVE EMPIRICAL STUDY

    Nov 1, 2004, 00:00

  • PDB6 THE COST OF TYPE-2 DIABETES IN UKRAINE

    Nov 1, 2004, 00:00

  • UC3 A FIVE-LEVEL VERSION OF EQ-5D

    Nov 1, 2004, 00:00

  • PNL29 ESTIMATING THE COST OF ILLNESS IN EUROPE-A MODEL WITH MULTIPLE SCLEROSIS AS AN EXAMPLE

    Nov 1, 2004, 00:00

  • PNL6 THE HOSPITAL COSTS OF PRIMARY STROKE PATIENTS MANAGEMENT IN POLAND

    Nov 1, 2004, 00:00

  • PBR1 COST OF KALIUM SUPPLEMENTATION WITH KALIPOZ PROLONGATUM OR KALDYUM FROM PAYER PERSPECTIVE IN POLAND

    Nov 1, 2004, 00:00

  • PMH2 GEO OBSERVATIONAL STUDY- 12 MONTHS DISEASE CHARACTERISTICS, SIDE EFFECTS AND SOCIOECONOMIC STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY

    Nov 1, 2004, 00:00

  • PES20 SUNBURNS AND QUALITY OF LIFE

    Nov 1, 2004, 00:00

  • PAR 12 HOW ADEQUATE DO RA-PATIENTS REPORT INDIRECT COSTS?-THE EXAMPLE OF A GERMAN COHORT

    Nov 1, 2004, 00:00

  • PMC21 AN EXPLORATION OF THE DISCREPANCIES BETWEEN HEALTH STATE VALUATIONS OF PATIENTS AND THE GENERAL POPULATION

    Nov 1, 2004, 00:00

  • QL8 DEVELOPMENT AND VALIDATION OF THE DIAPASON- A TREATMENT SATISFACTION QUESTIONNAIRE FOR INDIVIDUALS WITH TYPE-2 DIABETES

    Nov 1, 2004, 00:00

  • PMC17 THERES NO F IN UTILITY

    Nov 1, 2004, 00:00

  • PMC16 VISUAL ANALOGUE SCALES- ARE THE ELICITED PREFERENCES ANALOGUE?

    Nov 1, 2004, 00:00

  • PAR 13 COST-EFFECTIVENESS OFVALDECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN THE UK (UK) AND GERMANY

    Nov 1, 2004, 00:00

  • EE4 COMPARING TREATMENT COSTS ASSOCIATED WITH SCREENING FOR GLAUCOMAVS NOT SCREENING- EVALUATING THE ECONOMIC IMPACT OF THE NEW HEDIS MEASURE

    Nov 1, 2004, 00:00

  • NPI HEALTH-RELATED QUALITY OF LIFE IN NEUROMUSCULAR DISEASES

    Nov 1, 2004, 00:00

  • PAR6 ECONOMIC EVALUATION OF THERAPY WITH NSAIDAND WITH COX-2 IN SUBJECTS AGED 66 YEARS OR MORE

    Nov 1, 2004, 00:00

  • PIN1 CLINICAL PRACTICE GUIDELINE EVALUATION- NEONATAL INFECTION WITH MATERNAL HISTORY OF PREMATURE RUPTURE OF MEMBRANE (PROM)

    Nov 1, 2004, 00:00

  • PCV50 CHRONIC VENOUS DISEASE- PATIENTS PROFILE

    Nov 1, 2004, 00:00

  • PES17 LIVING WITH A DERMATOSIS- A NATIONAL SURVEY OF QUALITY OF LIFE IN BELGIUM

    Nov 1, 2004, 00:00

  • HP8 EXPLAINING THE LACK OF SUCCESS OF GENERIC DRUGS IN BELGIUM- A POLICY PERSPECTIVE

    Nov 1, 2004, 00:00

  • PCV75 THE APPLICATION OF TWO ANALYTIC METHODS TO INVESTIGATE THE INFLUENCE OF POOR INR CONTROL ON RISKS OF HOSPITALISATION FOR PATIENTS RECEIVING WARFARIN

    Nov 1, 2004, 00:00

  • PCV67 USE OF CLOPIDOGREL AFTER ISCHEMIC VASCULAR EVENTS IN THE THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PUK9 EVALUATION OF THE COST UTILITY OF SIROLIMUS VERSUS TACROLIMUS FOR IMMUNOSUPPRESSION FOR RENAL TRANSPLANTATION IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PCN8 COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY IN THE UK

    Nov 1, 2004, 00:00

  • PES2 ASSOCIATION BETWEEN MORTALITY AND VISUAL IMPAIRMENT ESTIMATED FROM A FRENCH NATIONAL SURVEY

    Nov 1, 2004, 00:00

  • PAA3 RESOURCE USE IN PATIENTS WITH EXACERBATIONS OF ASTHMA WITH DIFFERENT UNDERLYING DEGREES OF SEVERITY IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2004, 00:00

  • PDB11 PHARMACOECONOMIC ASPECTS OF USE OF INSULIN GLARGINE IN TREATMENT OF DIABETES MELLITUS TYPE 2 (DM T2) IN RUSSIA

    Nov 1, 2004, 00:00

  • PMW1 ECONOMIC EVALUATION OF THE ADMINISTRATION OF FOLLITROPIN- WITH A PEN DEVICE COMPARED WITH ADMINISTRATION OF MENOTROPIN BY CONVENTIONAL SYRINGE

    Nov 1, 2004, 00:00

  • PAA9 FROM SF-36TO UTILITY SCORES- A COMPARISON OF DIFFERENT ALGORITHMS IN DIFFERENT SETTINGS

    Nov 1, 2004, 00:00

  • PNL5 SOCIAL COSTS OF PARKINSON DISEASE IN ITALY

    Nov 1, 2004, 00:00

  • PCN36 THE VALUE OF THE USE OF ANASTROZOLE AS AN ALTERNATIVE ADJUVANT THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY

    Nov 1, 2004, 00:00

  • PMH4 THE COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER IN AUSTRALIA; A RETROSPECTIVE AUDIT

    Nov 1, 2004, 00:00

  • PBR10 ESTABLISHING HEMOPHILIA PATIENTS PREFERENCES IN PROPHYLAXIS- A CONJOINT ANALYSIS PILOT STUDY

    Nov 1, 2004, 00:00

  • POS9 EPIDEMIOLOGY OF OSTEOPOROSIS IN THE NETHERLANDS (1993-2002)

    Nov 1, 2004, 00:00

  • PBR12 CLINICAL AND SOCIO-DEMOGRAPHIC CHARACTERISTICS INFLUENCE PATIENTS PREFERENCES TOWARDS HEMOPHILIA TREATMENT

    Nov 1, 2004, 00:00

  • PAR11 A COST EFFICACY ANALYSIS ON ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS

    Nov 1, 2004, 00:00

  • DB3 DECREASED RATES OF MAJOR HYPOGLYCAEMIC EVENTS LEAD TO IMPROVED LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS BIPHASIC HUMAN INSULIN 30 IN TYPE 2 DIABETIC SUBJECTS IN DANISH, FINNISH, GERMAN, NORWEGIAN, SPANISH, SW ...

    Nov 1, 2004, 00:00

  • PMH30 COST-EFFECTIVENESS ANALYSIS IN THE AUSTRALIAN SETTING OF RISPERIDONE LONG-ACTING INJECTION FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA WHO ARE PARTIALLY ADHERENT TO THEIR MEDICATION

    Nov 1, 2004, 00:00

  • PPN4 COST-EFFECTIVENESS OF THE COMBINATION TRAMADOL PLUS PARACETAMOL IN TREATMENT OF SUBACUTE LOW BACK PAIN IN A DUTCH HEALTH CARE SETTING

    Nov 1, 2004, 00:00

  • PCV2 ACHIEVEMENT OF THE EUROPEAN 1998 LDL-C GOAL BY HYPERCHOLESTEROLAEMIC PATIENTS IN THE STELLAR TRIAL- AN EVIDENCE-BASED MEDICINE (EBM) APPROACH

    Nov 1, 2004, 00:00

  • PMH21 IS HEALTH-RELATED QUALITY OF LIFE EVALUATION DIFFERENT BETWEEN CLINICAL TRIALS AND OBSERVATIONAL STUDIES IN MAJOR DEPRESSIVE DISORDER?

    Nov 1, 2004, 00:00

  • PES6 COST EFFECTIVENESS OF LATANOPROST IN FIRST LINE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA IN THE UK

    Nov 1, 2004, 00:00

  • PUK6 COST OF RENAL TRANSPLANTATION IN BELGIUM

    Nov 1, 2004, 00:00

  • PCV40 COSTS OF ISCHEMIC STROKE TREATMENT IN RUSSIAN FEDERATION

    Nov 1, 2004, 00:00

  • PDB13 ECONOMIC EVALUATION OF THE STEPPED VERSUS ORDINARY CARE FOR PREVENTION OF TYPE-2 DIABETES IN THE JDPP- JAPAN DIABETES PREVENTION PROGRAM

    Nov 1, 2004, 00:00

  • PCV6 AN ECONOMIC EVALUATION OF CLOPIDOGREL VS. ASPIRIN IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH RISKATHEROTHROMBOTIC PATIENTS IN ITALY

    Nov 1, 2004, 00:00

  • PNL23 CHRONIC NEUROPATHIC PAIN (NEP) IMPACT ON PATIENT QUALITY OF LIFE AND DISABILITY- RESULTS FROM THE DONEGA STUDY

    Nov 1, 2004, 00:00

  • PAR9 A COST MINIMISATION ANALYSE FOR STUDYING THE EFFICIENCY OF BIOLOGIC THERAPIES (BT) IN RHEUMATOID ARTHRITIS (RA). OVERVIEW FOR THE SPANISH SETTING

    Nov 1, 2004, 00:00

  • PCV44 VKATREATMENT RELATED COSTS IN FRANCE IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION- COST DATA FROM THE INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT (ISAM)

    Nov 1, 2004, 00:00

  • PCN28 QUALITY OF LIFE AND SEXUALITY IN PATIENTS WITH RECTAL CANCER

    Nov 1, 2004, 00:00

  • PMC3 ECONOMIC EVALUATION IN LATIN AMERICA

    Nov 1, 2004, 00:00

  • HP3 PHARMACOECONOMIC EDUCATION AT NON-US COLLEGES OF PHARMACY

    Nov 1, 2004, 00:00

  • PHP13 THE HOSPITAL DIAGNOSTIC THERAPEUTIC PATHWAY OF PATIENTS AFFECTED BY CRITICAL ISCHEMIA OF THE LOWER LIMBS WHICH IS UNRESPONSIVE TO REVASCULARIZATION

    Nov 1, 2004, 00:00

  • PNL1 PREVALENCE, HEALTH RESOURCES USAGE AND COST OF VASCULAR DEMENTIA IN COMPARISON WITH ALZHEIMER DISEASE IN A POPULATION SETTING IN SPAIN

    Nov 1, 2004, 00:00

  • PAR14 COSTS OF RA IN GERMANY ON A MICRO-COSTING LEVEL

    Nov 1, 2004, 00:00

  • PCV2I ECONOMIC EVALUATION OF VARIOUS ANTIHYPERTENSIVE MONOTHERAPIES IN GREECE

    Nov 1, 2004, 00:00

  • PNL25 INTERNAL, EXTERNAL, AND CROSS-MODEL VALIDATION OF A MULTI-OUTCOME DECISION MODEL FOR PARKINSONS DISEASE

    Nov 1, 2004, 00:00

  • PCN42 POOLING CLINICAL AND COST OUTCOMES- A CASE STUDY OF BEST SUPPORTIVE CARE (BSC) IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC)

    Nov 1, 2004, 00:00

  • PNL18 COSTS AND OUTCOMES ASSOCIATED WITH THE USE OF BOTULINUM TOXIN TYPE A (BTX-A) IN THE TREATMENT OF FLEXED WRIST/CLENCHED FIST POST-STROKE SPASTICITY

    Nov 1, 2004, 00:00

  • PCN29 PROSTATE CANCER SPECIFIC SYMPTOMS IN A GERMAN REFERENCE POPULATION

    Nov 1, 2004, 00:00

  • PC VI THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN TAIWAN

    Nov 1, 2004, 00:00

  • PPN1 ESTIMATING THE INCIDENCE AND COSTS OF TREATING ADVERSE EVENTS IN PATIENTS TREATED WITH STRONG OPIOIDS FOR CHRONIC NON-MALIGNANT PAIN

    Nov 1, 2004, 00:00

  • PAR2I CROSS-SURVEY OF RHEUMATOLOGISTS AND GP AWARENESS AND KNOWLEDGE OF FIBROMYALGIA

    Nov 1, 2004, 00:00

  • PCV46 SCREENING FOR ABDOMINAL AORTIC ANEURYSM IN MEN. AN ECONOMIC EVALUATION BASED ON A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2004, 00:00

  • CSI TEGASEROD IS COST-EFFECTIVE IN THE TREATMENT OF PATIENTS WITH IBS- AN ECONOMIC ANALYSIS OF THE TENOR (TEGASEROD IN NORDIC COUNTRIES) STUDY

    Nov 1, 2004, 00:00

  • PDB12 COSTS OF TYPE-2 DIABETES MELLITUS- A COMPARISON BETWEEN DIABETIC AND NON-DIABETIC SUBJECTS

    Nov 1, 2004, 00:00

  • PAR7 FIBROMYALGIA COST OF CARE

    Nov 1, 2004, 00:00

  • NP2 COST ASSOCIATED WITH PERSISTENCY AMONG PATIENTS WITH PARTIAL SEIZURE DISORDER SWITCHING TO OXCARBAZEPINE MONOTHERAPY

    Nov 1, 2004, 00:00

  • CS4 ANTIPSYCHOTIC PATTERNS AND TREATMENT COST IN FRANCE

    Nov 1, 2004, 00:00

  • PDB31 COMPARISON OF BLOOD PRESSURE AND ATTRIBUTABLE HEALTHCARE COSTS BY DIHYDROPYRIDINE VS NONDIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INITIATED FOR HYPERTENSION IN DIABETES MELLITUS PATIENTS, AND MONITORING OF RENAL PARAMETERS

    Nov 1, 2004, 00:00

  • PHP29 PATHOLOGY RELATED DIFFERENCES INVARIANCE OF DRUG INSURANCE COST IN HOSPITAL STAYS- FEASIBILITY OF FIXED FUNDING IN PATHOLOGIES WITH REDUCED COST VARIANCE

    Nov 1, 2004, 00:00

  • PDB17 ABSOLUTE AND INCREMENTAL EFFECTS OF THERAPYSWITCHING THRESHOLDS ON THE COST-EFFECTIVENESS OF TREATMENTS FOR OBESE TYPE-2 DIABETES PATIENTS IN GERMANY

    Nov 1, 2004, 00:00

  • QL5 VALIDATION OF THE GERMAN PROSTATE SPECIFIC MODULE (PSM)

    Nov 1, 2004, 00:00

  • PIN15 ACUTE ROTAVIRUS GASTROENTERITIS- BURDEN OF DISEASE AND COST OF ILLNESS AMONG YOUNG CHILDREN IN GERMANY

    Nov 1, 2004, 00:00

  • PCN6 HOSPITALIZARON COSTS OF PATIENTS WITH INFECTIONS WHO HAVE LUNG CANCER OR NEUTROPENIA IN SWEDEN-A RETROSPECTIVE DATABASE STUDY

    Nov 1, 2004, 00:00

  • PNL32 HEALTHCARE RESOURCES USED BY SPANISH PRIMARY CARE PHYSICIANS IN PATIENTS WITH SUBJECTIVE MEMORY COMPLAINTS OR COGNITIVE IMPAIRMENT.THE ISSEA STUDY

    Nov 1, 2004, 00:00

  • PGI6 ECONOMIC EVALUATION OF RABEPRAZOLE VS. OMEPRAZOLE IN THE CURATIVE TREATMENT OF REFLUX OESOPHAGITIS

    Nov 1, 2004, 00:00

  • PIN31 COSTS AND EFFECTS OF CHLAMYDIAL SCREENING PROGRAMS- DYNAMIC VERSUS STATIC MODELING

    Nov 1, 2004, 00:00

  • PES15 IMPACT OF ATOPIC DERMATITIS ON PARENTS QUALITY OF LIFE AND USE OF DIRECT RESOURCES IN PATIENTS BETWEEN 2 AND 12 YEARS OLD. DAES STUDY

    Nov 1, 2004, 00:00

  • PCNII COST-EFFECTIVENESS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV PAMIDRONATE IN THE TREATMENT OF BREAST CANCERWITH BONE METASTASES IN PATIENTS UNDERGOING IV CHEMOTHERAPY IN THE UK

    Nov 1, 2004, 00:00

  • PCN2I A PHARMACOECONOMIC MODEL OF THE COST-EFFECTIVENESS OF GEFITINIB ('IRESSA') COMPARED WITH BEST SUPPORTIVE CARE (BSC) IN THIRD-LINE TREATMENT OF PATIENTS WITH REFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN THE UK

    Nov 1, 2004, 00:00

  • PPN13 THE UNDER TREATMENT OF DEPRESSION IN CHRONIC PAIN

    Nov 1, 2004, 00:00

  • PPT2 THE DEFICIT IN HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR GROWTH HORMONE DEFICIENT (GHD) PATIENTS IN SPAIN AND ENGLAND WALES- A COMPARISON WITH NORMATIVE POPULATION DATA

    Nov 1, 2004, 00:00

  • PCV63 OVER-ADHERENCE WITH ANTIHYPERTENSIVE MEDICATIONS AMONG CENTRAL TEXAS VETERANS

    Nov 1, 2004, 00:00

  • PIN6 CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF ANTIVIRAL COMBINATION THERAPY WITH PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS C ADMINISTERED ACCORDING TO THE NEW GENOTYPESPECIFIC GUIDELINES

    Nov 1, 2004, 00:00

  • PMH24 EFFECT OF ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIA

    Nov 1, 2004, 00:00

  • PCN27 PATIENT PREFERENCE FORANASTROZOLE AS ADJUVANT HORMONAL THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY

    Nov 1, 2004, 00:00

  • PBR8 PHYSICIANS PREFERENCES FOR HEMOPHILIA TREATMENT EVALUATED BY CONJOINT ANALYSIS

    Nov 1, 2004, 00:00

  • PUK15 PATIENTS UNDERGOING PERITONEAL DILISIS HAVE BETTER PERCEIVED HEALTH IN SEVERAL SPECIFIC PROBLEMS RELATED WITH RENAL DISEASE THAN PATIENTS UNDERGOING HEMODIALYSIS

    Nov 1, 2004, 00:00

  • PHP36 REIMBURSMENT POLICY IN TURKEY- NEW CONSENSUS

    Nov 1, 2004, 00:00

  • PIN19 A COMPARISON OF COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS FIRST TREATMENT OF CHRONIC HEPATITIS C IN THE UK

    Nov 1, 2004, 00:00

  • PCVI3 ECONOMIC ASSESSMENT OF EZETIMIBE CO-ADMINISTRATION IN A HUNGARIAN CHD PATIENT COHORT NOTAT CHOLESTEROL GOAL ON SIMVASTATIN MONOTHERAPY

    Nov 1, 2004, 00:00

  • PHP17 MEDICINAL CANNABIS IN THE NETHERLANDS

    Nov 1, 2004, 00:00

  • NP4 12-MONTHS COSTS OF PARKINSONS DISEASE IN GERMANY-RESULTS OF A PROSPECTIVE STUDY

    Nov 1, 2004, 00:00

  • PUK12 LONG-TERM COST-EFFECTIVENESS MODELLING OF FEEDBACK MICROWAVE THERMOTHERAPY VERSUS DRUG TREATMENT IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS

    Nov 1, 2004, 00:00

  • PMC19 CHRONIC DISEASE SCORES AMONG SENIORS IN ALBERTA, CANADA

    Nov 1, 2004, 00:00

  • PBR3 ECONOMIC MODELING OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHFPFM)- VALUE OF POTENTIAL VIRAL TRANSMISSION REDUCTION DUE TO PLASMA/ALBUMIN-FREE FORMULATION

    Nov 1, 2004, 00:00

  • PNL12 HEALTHCARE UTILIZATION AND SOCIOECONOMIC ASPECTS OF NEUROMUSCULAR DISEASES

    Nov 1, 2004, 00:00

  • PNL16 A COMPARATIVE STUDY ON RESOURCE USE, COSTS AND CAREGIVER BURDEN BETWEEN RASAGILINE AND ENTACAPONE IN FLUCTUATING PARKINSONS DISEASE (PD) PATIENTS

    Nov 1, 2004, 00:00

  • POB5 COST AND QUALITY OF LIFE IN OBESITY

    Nov 1, 2004, 00:00

  • PAR 19 SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH RHEUMATOLOGISTS IN 2003

    Nov 1, 2004, 00:00

  • HP6 MODELLING USE OF HOSPITAL SERVICES AS A FUNCTION OF NEEDS AND SUPPLY IN ITALY

    Nov 1, 2004, 00:00

  • PAA5 A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF FLUTICASONE AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA

    Nov 1, 2004, 00:00

  • PDB18 SEARCHING FOR DIABETES MELLITUS (DM) IN PRIMARY CARE-IT IS GOOD VALUE-FOR-MONEY IN POLAND? (COST OF DIAGNOSING DIABETES MELLITUS IN PRIMARY CARE CONDITION IN POLAND)

    Nov 1, 2004, 00:00

  • PCNI4 ALCEA (ADVANCED LUNG CANCER ECONOMIC ASSESSMENT)

    Nov 1, 2004, 00:00

  • PUK2 COST-EFFECTIVENESS ANALYSIS OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN SPAIN

    Nov 1, 2004, 00:00

  • PNL8 COST-EFFECTIVENESS OF THROMBOLYSIS WITH RT-PA FOR ACUTE ISCHEMIC STROKE IN TAIWAN

    Nov 1, 2004, 00:00

  • PMC13 DEVELOPING THE EUROPEAN NETWORK OF HEALTH ECONOMIC EVALUATIONS DATABASES (EURONHEED)- THE ACTIVITIES OF ONE CENTRE TO FULFILL BOTH INTERNATIONAL AND LOCAL NEEDS

    Nov 1, 2004, 00:00

  • PUK11 COST-CONSEQUENCES OF TREATING WOMEN WITH STRESS URINARY INCONTINENCE WITH DULOXETINE FROM THE PERSPECTIVE OF THE STATUTORY HEALTH INSURANCE IN GERMANY

    Nov 1, 2004, 00:00

  • PCN3 COST-EFFECTIVENESS OF BORTEZOMIB (VELCADE) FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

    Nov 1, 2004, 00:00

  • PNL7 COSTS OF STROKE UNIT CARE IN GERMANY

    Nov 1, 2004, 00:00

  • PMH26 SSRI UTILIZATION AND PERSISTENCE IN A CALIFORNIA MEDICAID POPULATION

    Nov 1, 2004, 00:00

  • PMH12 THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIDEPRESSANT THERAPY IN MAJOR DEPRESSIVE DISORDER IN THE UK

    Nov 1, 2004, 00:00

  • PAR27 ASSESMENT OF QUALITY OF LIFE (QOL) IN ADULTS WITH JUVENILE IDIOPATIC ARTHRITIS (Alj) DIAGNOSIS IN MEXICO- THE DISABILITY IMPACT

    Nov 1, 2004, 00:00

  • PNL13 PROFILE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME AND ESTIMATION OF THEIR ANNUAL COST IN AN AMBULATORY CARE SETTING, IN FRANCE

    Nov 1, 2004, 00:00

  • PHP16 PHARMACOECONOMICS INTRODUCTION IN THE CREATION OF POSITIVE DRUG LIST IN BULGARIA

    Nov 1, 2004, 00:00

  • DB4 PROOF OF CONCEPT OF A WIRELESS APPROACH FOR ENABLING COMMUNICATIONS BETWEEN GERMAN PHYSICIANS AND THEIR PATIENTS WITH TYPE 2 DIABETES TREATED WITH NATEGLINIDE

    Nov 1, 2004, 00:00

  • PDB9 THE VALUE OF ORAL MONOTHERAPY ALTERNATIVES IN THE FIRST-LINE TREATMENT OF TYPE-2 DIABETES MELLITUS

    Nov 1, 2004, 00:00

  • IN3 ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN GREECE

    Nov 1, 2004, 00:00

  • POB1 OBESITYANDTHE RISK OF UPPER RESPIRATORY TRACT INFECTIONS

    Nov 1, 2004, 00:00

  • PMC1 BOOTSTRAP CONFIDENCE INTERVALS FOR THE ANGULAR TRANSFORMED ICER- ARE MORE SOPHISTICATED METHODS THE BETTER CHOICE?

    Nov 1, 2004, 00:00

  • PDB25 QUALITY OF LIFE IN SUBJECTS WITH AND WITHOUT TYPE-2 DIABETES MELLITUS

    Nov 1, 2004, 00:00

  • PRS3 PHARMACOECONOMY AND ANTIBIOTIC TREATMENT WITHIN THE SLOVAK REPUBLIC

    Nov 1, 2004, 00:00

  • PES25 ASSOCIATION BETWEEN VITAMIN SUPPLEMENTS USAGE AND PRESENCE OF AGE-RELATED MACULAR DEGENERATION IN A LATINO POPULATION ADJUSTING FOR SELECTION BIAS USING PROPENSITY SCORES

    Nov 1, 2004, 00:00

  • PES26 ANALYSIS OF RUSSIAN PHARMACEUTICAL MARKET OF ANTI-GLAUCOMA MEDICINES IN THE PERIOD 2000-2003

    Nov 1, 2004, 00:00

  • PCNI6 COMPARATIVE COSTS OF GEMCITABINE/CISPLATIN, PACLITAXEL/CARBOPLATIN AND VINORELBINE/CISPLATIN IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN GERMANY

    Nov 1, 2004, 00:00

  • PCN45 MODELING EFFECT IN PHARMACOECONOMICS ANALYSIS USING ARTIFICIAL NEURAL NETWORKS

    Nov 1, 2004, 00:00

  • PCV29 COST-EFFECTIVENESS OF REDUCTION IN CARDIOVASCULAR OUTCOMES WITH ATORVASTATIN IN PATIENTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS.TREATED FOR HYPERTENSION- THE ASCOT-LLA STUDY

    Nov 1, 2004, 00:00

  • PGI3 COST-EFFECTIVENESS OF ESOMEPRAZOLE COMPARED TO PANTOPRAZOLE AND GENERIC OMEPRAZOLE IN ENDOSCOPY POSITIVE GERD PATIENTS IN GERMANY

    Nov 1, 2004, 00:00

  • PCV43 THE IMPACT OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN USAGE ON OUTCOMES OF TREATMENT MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES (ACS) IN RUSSIA

    Nov 1, 2004, 00:00

  • PNL15 RETROSPECTIVE EVALUATION OF THE DOSE OF DYSPORT IN THE CLINICAL MANAGEMENT OF CERVICAL DYSTONIA OR BLEPHAROSPASM-THE REAL DOSE STUDY EXPANSION-COST CONSIDERATIONS BASED ON DRUG START

    Nov 1, 2004, 00:00

  • PES5 A COST-EFFECTIVENESS ANALYSIS OF LATANOPROST IN THE TREATMENT OF OPEN ANGLE GLAUCOMA IN SPAIN

    Nov 1, 2004, 00:00

  • PCV35 ECONOMIC ASSESSMENT OF SWITCHING TO EZETIMIBE CO-ADMINISTERED WITH SIMVASTATIN IN SPAIN FORA COHORT OF PATIENTS NOT AT GOAL ON ATORVASTATIN MONOTHERAPY

    Nov 1, 2004, 00:00

  • PCV73 COSTS ASSOCIATED WITH ALTERNATIVE FETAL CARDIOLOGY REFERRAL MODES- APPLICATION OF PROPENSITY SCORE MATCHING

    Nov 1, 2004, 00:00

  • PNL20 A SIMPLIFIED SEVERITY SCALE FOR THE ASSESSMENT OF RESTLESS LEGS SYNDROME- THE DESYR STUDY GROUP

    Nov 1, 2004, 00:00

  • PMC4 CAN ECONOMIC EVALUATIONS BE MADE MORE TRANSFERABLE?

    Nov 1, 2004, 00:00

  • PCN30 IMPROVED TOXICITY PROFILE OF PEMETREXEDVS DOCETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS TRANSLATES TO COST SAVINGS IN SPAIN

    Nov 1, 2004, 00:00

  • PNL28 CENTERED REGRESSION FUNCTIONS AS A TECHNIQUE TO IMPROVE FLEXIBILITY AND TRANSFERABILITY OF MARKOV MODELS

    Nov 1, 2004, 00:00

  • PIN2 COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN NOSOCOMIAL PNEUMONIA IN GERMANY

    Nov 1, 2004, 00:00

  • PAA6 IMPACT OF A DISEASE MANAGEMENT PROGRAM ON CONTROL OF ASTHMA IN NORMANDY

    Nov 1, 2004, 00:00

  • PDB22 COST-EFFECTIVENESS ANALYSIS OF THE DIABETES PREVENTION PROGRAM IN A SPANISH SETTING

    Nov 1, 2004, 00:00

  • PCV53 TRENDS IN PREVALENCE, AWARENESS, TREATMENT.AND CONTROL OF HYPERTENSION AMONG CHINESE AMERICANS FROM 2001 THROUGH 2004

    Nov 1, 2004, 00:00

  • DB2 LABOR MARKET EFFECTS OF INSULIN DEPENDENT AND NON-INSULIN DEPENDENT DIABETES AMONG CANADIAN LABOR FORCE

    Nov 1, 2004, 00:00

  • PES8 RESOURCE UTILIZATION OF END-STAGE GLAUCOMA PATIENTS RECEIVING LOW VISION CARE- A US MULTI-SITE RETROSPECTIVE STUDY

    Nov 1, 2004, 00:00

  • POS7 PERSISTENCE AND COMPLIANCE WITH BISPHOSPHONATE THERAPY AMONG POST-MENOPAUSAL OSTEOPOROTIC WOMEN

    Nov 1, 2004, 00:00

  • PRS4 COST OF TREATMENT AND REIMBURSEMENT OF HOSPITALIZED COMMUNITY-ACQUIRED PNEUMONIA WITH I.V. MOXIFLOXACIN COMPARED TO STANDARD ANTIBIOTIC TREAMENT IN GERMANY

    Nov 1, 2004, 00:00

  • PMH13 THE COST-EFFECTIVENESS OF PAROXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER IN JAPAN

    Nov 1, 2004, 00:00

  • PCV66 POOLED EFFICACY OF DISEASE MANAGEMENT PROGRAMS IN PATIENTS WITH CONGESTIVE HEART FAILURE-A SYSTEMATIC REVIEW

    Nov 1, 2004, 00:00

  • CN2 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB CHOP VERSUS CHOP IN PATIENTS WITH AGGRESSIVE NONHODGKIN LYMPHOMA

    Nov 1, 2004, 00:00

  • PCN22 A SYSTEMATIC EVALUATION OF THE IMPACT OF THE SCREENING INTERVAL ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DIFFERENT CERVICAL CANCER SCREENING TECHNIQUES

    Nov 1, 2004, 00:00

  • PMH16 TOTAL HEALTH CARE CONSUMPTION AND COSTS OF SICKNESS FUND INSURED PATIENTS IN THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PGI7 COST BENEFIT ANALYSIS OF TWO TREATMENTS FOR PATIENTS WITH CHOLEDOCHOLITHIASIS AND CHOLECYSTOLITHIASIS

    Nov 1, 2004, 00:00

  • PMW6 SHORT-TERM AND LONG-TERM PSYCHOSOCIAL CONSEQUENCES OF FALSE POSITIVE SCREENING MAMMOGRAPHY-DEVELOPMENT OF TWO NEW QUESTIONNAIRE BASED ON THE PSYCHOLOGICAL CONSEQUENCES QUESTIONNAIRE (THE PCQ)

    Nov 1, 2004, 00:00

  • PCNI7 DOES GEMCITABINE PLUS CISPLATIN PROVIDE VALUE FOR MONEY IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER IN THE UK?

    Nov 1, 2004, 00:00

  • PHP38 USE OF PATIENT-REPORTED OUTCOMES IN EVALUATION OF HEART FAILURE DEVICE THERAPY- THE REGULATORY PERSPECTIVE

    Nov 1, 2004, 00:00

  • PMC2 A FRAMEWORK FOR HANDLING UNCERTAINTY AND VARIABILITY IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMS

    Nov 1, 2004, 00:00

  • PDB23 COST-EFFECTIVENESS OF ACARBOSE FOR THE MANAGEMENT OF IMPAIRED GLUCOSE TOLERANCE IN SWEDEN

    Nov 1, 2004, 00:00

  • MC4 FLEXIBILITY AND TRANSPARENCY OF BAYESIAN NETWORKS- MODELING THE ECONOMIC IMPACT OF DRUG-ELUTING CORONARY STENTS

    Nov 1, 2004, 00:00

  • PMH9 A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM, GENERIC CITALOPRAM AND VENLAFAXINE AS A FIRST-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PCN37 DIFFERENCES IN TREATMENT PRACTICE, RESPONSE RATES AND COST OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT FOR ANEMIC CANCER PATIENTS- A RETROSPECTIVE ANALYSIS FROM SWEDEN

    Nov 1, 2004, 00:00

  • PUK20 IMPLICATIONS OF OVERACTIVE BLADDER ICD-9 CODE CHANGES AND USE OF CODES IN A MANAGED CARE POPULATION

    Nov 1, 2004, 00:00

  • PHP5 DECISION MAKING IN ITALIAN HEALTH CARE- ARE ECONOMIC STUDIES USED BY DECISION MAKERS?

    Nov 1, 2004, 00:00

  • PHP6 PRESCRIPTION PATTERN OF ALIMENTARYTRACT DRUGS AFTER CHANGES OF DRUG BENEFIT STATUS IN KOREA

    Nov 1, 2004, 00:00

  • PMC20 DEVELOPMENT OF A NUTRITION RELATED QUALITY OF LIFE SCALE IN CHILDREN

    Nov 1, 2004, 00:00

  • MC1 COMPLIANCE, ADHERENCE, AND PERSISTENCE- A COMPARISON OF THREE METHODOLOGIES FOR EVALUATING PATIENT COMPLIANCE USING PRESCRIPTION CLAIMS DATA

    Nov 1, 2004, 00:00

  • PRS2 COST OF CHRONIC BRONCHITIS (CB) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN FRANCE- THE BRONCHECO STUDY

    Nov 1, 2004, 00:00

  • PCNIO COST-EFFECTIVENESS-ANALYSIS OF BREAST CANCER DIAGNOSIS WITH CAD (COMPUTER AIDED DETECTION)

    Nov 1, 2004, 00:00

  • PAR8 HEALTH ECONOMIC EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH ADALIMUMAB

    Nov 1, 2004, 00:00

  • PCV41 COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF HYPERCHOLESTEROLEMIA IN CATALONIA, SPAIN

    Nov 1, 2004, 00:00

  • PMH23 ADHD TREATMENT AND CO-MORBIDITIES- BASELINE RESULTS FROM THE OBSERVATIONAL STUDY ADORE IN GERMANY

    Nov 1, 2004, 00:00

  • PCV70 DECISION ANALYSIS AND COSTS OF LOW MOLECULAR WEIGHT HEPARINS- A CASE STUDY IN FRANCE

    Nov 1, 2004, 00:00

  • PMC23 REVIEW AND ASSESSMENT OF THE ECONOMIC EVALUATION STUDIES ON HEALTH CARE IN MEXICO

    Nov 1, 2004, 00:00

  • PCN4 COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER

    Nov 1, 2004, 00:00

  • PDB15 A COST-EFFECTIVENESS ANALYSIS OF SWITCHING TYPE-2 DIABETES PATIENTS FROM IMMEDIATE-RELEASE METFORMIN (GLUCOPHAGE) TO A NEW EXTENDEDRELEASE FORMULATION OF METFORMIN (GLUCOPHAGEXR)

    Nov 1, 2004, 00:00

  • PCV32 SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS 1442-A PROSPECTIVE 3-YEAR PHARMACOECONOMIC STUDY

    Nov 1, 2004, 00:00

  • PCV60 TREATMENT OF NEWLY-DIAGNOSED HYPERTENSIVE PATIENTS IN ITALYA RETROSPECTIVE COHORT STUDY IN PRIMARY CARE

    Nov 1, 2004, 00:00

  • PCN24 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIAL (GREAT) IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER IN TAIWAN

    Nov 1, 2004, 00:00

  • CV1 A HEALTH ECONOMIC EVALUATION OF ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE

    Nov 1, 2004, 00:00

  • PCN33 HEALTH UTILITY VALUES FOR CANCER RELATED ANAEMIA

    Nov 1, 2004, 00:00

  • PMC5 ARE THE BEST AVAILABLE, MOST APPLICABLE CLINICAL EFFECTIVENESS DATA USED IN ECONOMIC EVALUATIONS OF DRUG THERAPIES?

    Nov 1, 2004, 00:00

  • PDB27 A MULTIDIMENSIONAL HEALTH CARE INTERVENTION ASSESSMENT- THE CO-ORDINATED DIABETES HEALTHCARE NETWORK

    Nov 1, 2004, 00:00

  • PNL17 MARKOV MODEL OF ADJUNCTIVE ANTIEPILEPTIC TREATMENT FOR CHILDREN-A COMPARISON OF TOPIRAMATE AND LAMOTRIGINE

    Nov 1, 2004, 00:00

  • PCV26 THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY

    Nov 1, 2004, 00:00

  • MC6 PRODISQ A MODULAR QUESTIONNAIRE ON PRODUCTIVITY AND DISEASE FOR ECONOMIC EVALUATION STUDIES IN PATIENT SETTINGS AND ORGANISATIONAL SETTINGS

    Nov 1, 2004, 00:00

  • PAR28 ASSESSING INTANGIBLES IN BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS (RA). A WILLINGNESS TO PAY (WTP) STUDY IN SPANISH PATIENTS

    Nov 1, 2004, 00:00

  • QL4 PATIENT-RATED UTILITIES IN POSTMENOPAUSAL EARLY BREAST CANCER (EBC)-A CROSS-COUNTRY COMPARISON

    Nov 1, 2004, 00:00

  • PGI5 COSTS BENEFITS WITH ESOMEPRAZOLE 20MG 'ONDEMAND' TREATMENT IN GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS IN BELGIUM

    Nov 1, 2004, 00:00

  • PMC14 PERSONAL DRUG UTILIZATION REPORT (PDUR)-A CONTRIBUTION TO COST REDUCTION AND PATIENT EMPOWERMENT

    Nov 1, 2004, 00:00

  • PES19 SENSITIVE SKIN- QUALITY OF LIFE IMPACT

    Nov 1, 2004, 00:00

  • PCOI DRUG USE PROFILES AFTER HOSPITALIZARON FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE NETHERLANDS AND THE RISK ON RE-HOSPITALIZATION

    Nov 1, 2004, 00:00

  • PCV68 POPULATION IMPACT OF LOSARTAN USE ON STROKE IN FRANCE

    Nov 1, 2004, 00:00

  • PMH3 FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED ON RISPERIDONE OR OLANZAPINE- A TIME-TO-EVENT ANALYSIS

    Nov 1, 2004, 00:00

  • PAA8 COST ESTIMATION IN CLINICAL PIGGY-BACK STUDIES WITH DISCONTINUATIONS-COMPARISON OF DIFFERENT APPROACHES

    Nov 1, 2004, 00:00

  • POB2 SOCIAL COST OF OVERWEIGHT AND OBESITY- SPESA STUDY

    Nov 1, 2004, 00:00

  • PCNI8 A COST COMPARISON OF GEMZAR PLUS CISPLATIN WITH OTHER NOVEL AGENTS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2004, 00:00

  • HP4 DRUG COSTS DEVELOPMENT AFTER PATENT EXPIRY IN THE THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PNL24 COMPARING CLASSIFICATION AND REGRESSION TREE ANALYSIS WITH MULTIPLE REGRESSION FOR TRANSLATING A CLINICAL PARKINSONS DISEASE SCALE INTO UTILITIES

    Nov 1, 2004, 00:00

  • PUK17 EVALUATION OF TREATMENT OF FEMALE URINARY INCONTINENCE WITH THE ICIQ-UI SF QUESTIONNAIRE

    Nov 1, 2004, 00:00

  • PCV39 MODELING THE ECONOMIC CONSEQUENCES OF IMPLANTING DUAL CHAMBER VS. SINGLE CHAMBER PACEMAKERS IN THE UK

    Nov 1, 2004, 00:00

  • PDB20 COST AND OUTCOMES OF THE DIABETES CLINIC IN A COMMUNITY HOSPITAL, MAE HONG SON, THAILAND

    Nov 1, 2004, 00:00

  • PUK4 PATIENT PERCEPTION OF OAB DRUG THERAPY SUCCESS IS ASSOCIATED WITH LESS HEALTHCARE RESOURCE USE

    Nov 1, 2004, 00:00

  • PAR20 PEOPLES PREFERENCES FOR WHO SHOULD GETTHE NEXT JOINT REPLACEMENT

    Nov 1, 2004, 00:00

  • PRS5 COSTS OF COMMUNITY-ACQUIRED PNEUMONIA FROM THE HOSPITALS PERSPECTIVE IN GERMANY-FINAL RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2004, 00:00

  • PCN39 QUALITY ASSURANCE IN CANCER CHEMOTHERAPY THROUGH PHARMACEUTICAL CARE DOCUMENTATION

    Nov 1, 2004, 00:00

  • IN2 IS PROVISION OF ANTI-VIRAL INFLUENZA TREATMENT A SOUND INVESTMENT FOR PRIVATE AND PUBLIC EMPLOYERS IN THE UK?

    Nov 1, 2004, 00:00

  • PCV76 USING A PATTERN MIXTURE MODEL TO UNDERSTAND THE IMPACT OF NON-RANDOM MISSING DATA IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOING NON-CARDIAC VASCULAR SURGERY

    Nov 1, 2004, 00:00

  • PNL3 PREDICTORS FOR DIRECT AND INDIRECT COSTS IN PARKINSONS DISEASE

    Nov 1, 2004, 00:00

  • PCN35 VALUATION OF SOCIETAL PREFERENCE BETWEEN THERAPIES FOR CANCER-RELATED ANAEMIA (CRA)- RECOMBINANT HUMAN ERYTHROPOETIN (RH-EPO) VERSUS BLOOD TRANSFUSION

    Nov 1, 2004, 00:00

  • PCV47 DECISION ANALYSIS ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS FOR THE TREATMENT OF HEART FAILURE

    Nov 1, 2004, 00:00

  • PCV3I COST OF IN-PATIENT CARE AFTER ADMISSION FOR WARFARIN ASSOCIATED ADVERSE DRUG REACTIONS

    Nov 1, 2004, 00:00

  • PHP20 PROPER DRUG MANAGEMENT IN PHARMACY-THE ROLE OF PHARMACOECONOMICSAS PERCEIVED BY POLISH PHARMACISTS

    Nov 1, 2004, 00:00

  • POB3 EVALUATION OF THE COST-UTILITY OF ORLISTAT (XENICAL) IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PPN2 RESOURCE UTILISATION OF PATIENTS WITH CHRONIC PAIN CONDITIONS BEFORE AND DURING TREATMENT WITH LONG-ACTING OPIOIDS IN GERMANY

    Nov 1, 2004, 00:00

  • POS1 COST-EFFECTIVENESS OF RISENDRONATE THERAPY COMPARED TO ALENDRONATE IN POST-MENOPAUSAL WOMEN AT HIGH RISK OF OSTEOPOROTIC FRACTURE- A TAIWAN ANALYSIS

    Nov 1, 2004, 00:00

  • CN4 COST-EFFECTIVENESS OF SAMARIUM-153-EDTMP COMPARED TO CONVENTIONAL PAIN THERAPY IN GERMANY

    Nov 1, 2004, 00:00

  • PPT1 COST-OF-ILLNESS STUDY IN ACROMEGALIC PATIENTS IN ITALY

    Nov 1, 2004, 00:00

  • PMW5 INFERTILITY TREATMENT POLICIES IN GERMANY AND THE UNITED KINGDOM-WILLINGNESS TO PAY AMONG AFFECTED COUPLES

    Nov 1, 2004, 00:00

  • Abstracts Index

    Nov 1, 2004, 00:00

  • PIN9 COMPARING COSTS AND EFFECTIVENESS OF HAART TIMING IN HIV INFECTION- EVIDENCE FROM THE I.CO.N.A. COHORT (ON BEHALF OF THE I.CO.N.A. STUDY GROUP)

    Nov 1, 2004, 00:00
  • «
  • 161
  • 162
  • 163 (current)
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • »